LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

Poly (ADP-ribose) polymerase inhibitors (PARPis) are becoming increasingly meaningful in oncology, and their therapeutic drug monitoring (TDM) might be beneficial for patients. Several bioanalytical methods have been reported for PARPis quantification in human plasma, but advantages might be obtaine...

Full description

Bibliographic Details
Main Authors: Giovanni Canil, Marco Orleni, Bianca Posocco, Sara Gagno, Alessia Bignucolo, Marcella Montico, Rossana Roncato, Serena Corsetti, Michele Bartoletti, Giuseppe Toffoli
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Pharmaceutics
Subjects:
LC-MS/MS
PARP inhibitors
olaparib
rucaparib
niraparib
human plasma
Online Access:https://www.mdpi.com/1999-4923/15/5/1524

Internet

https://www.mdpi.com/1999-4923/15/5/1524

Similar Items